Fezolinetant for menopausal vasomotor symptoms in women unsuitable for hormone therapy

Phase 3, randomised, double-blind trial in vasomotor symptoms comparing Fezolinetant 45 mg with Placebo (2 arms). Primary endpoint: Mean change in frequency of moderate to severe vasomotor symptoms from baseline to week 24. Started Aug 2021; status: completed.